Bioscience Explained | Vol 1 | Nr 1
... design (Figure 9), which makes the system simpler to use. The ECG/G-force biotelemetry system consists of an ECG/G-force biotelemetry transmitter unit (TX-unit, Figure 10 — shown here without the G-force sensor) and a receiver unit (RX-unit, Figure 11). The TX unit amplifies the ECG signal from the ...
... design (Figure 9), which makes the system simpler to use. The ECG/G-force biotelemetry system consists of an ECG/G-force biotelemetry transmitter unit (TX-unit, Figure 10 — shown here without the G-force sensor) and a receiver unit (RX-unit, Figure 11). The TX unit amplifies the ECG signal from the ...
DOI: 10.1161/CIRCULATIONAHA.106.661983 published online Jul
... eart failure is a common cardiovascular syndrome that may occur in conjunction with either normal or abnormal left ventricular (LV) ejection fraction (EF). Patients with reduced EF have predominantly systolic dysfunction, whereas those with heart failure symptoms despite normal EF (HFNEF) are though ...
... eart failure is a common cardiovascular syndrome that may occur in conjunction with either normal or abnormal left ventricular (LV) ejection fraction (EF). Patients with reduced EF have predominantly systolic dysfunction, whereas those with heart failure symptoms despite normal EF (HFNEF) are though ...
Redalyc.Treatment of Chronic Atrial Fibrillation During Surgery for
... In the postoperative six months follow-up, 18 (90%) patients continued with regular atrial rhythm, one (5%) patient returned to atrial fibrillation and one patient presented with sinus bradycardia, requiring endocardial pacemaker implantation (5%). During hospitalization and 12 weeks after surgery, ...
... In the postoperative six months follow-up, 18 (90%) patients continued with regular atrial rhythm, one (5%) patient returned to atrial fibrillation and one patient presented with sinus bradycardia, requiring endocardial pacemaker implantation (5%). During hospitalization and 12 weeks after surgery, ...
English
... literature suggested, the possibility of a unique peculiarity in rheumatic patients as the QT interval duration, possibly an innate tendency toward this prolongation, which would later trigger acute rheumatic disease in the heart, in the presence of an immune mechanism. One example of this behavior ...
... literature suggested, the possibility of a unique peculiarity in rheumatic patients as the QT interval duration, possibly an innate tendency toward this prolongation, which would later trigger acute rheumatic disease in the heart, in the presence of an immune mechanism. One example of this behavior ...
Antianginal (Anti-ischaemic) Drugs
... To improve exercise tolerance in stable angina and reduce angina frequency. ADR: excess bradycardia, important adverse effect is visual disturbance. Ivabradine is indicated in chronic stable angina in patients ...
... To improve exercise tolerance in stable angina and reduce angina frequency. ADR: excess bradycardia, important adverse effect is visual disturbance. Ivabradine is indicated in chronic stable angina in patients ...
Atrial Size Independently Correlates with the Development of
... of abnormal atriograms under right atrium mapping,(23) fragmentation of atrial activity elicited by premature stimulation and the vulnerability index.(9,10,24) Although these parameters seem to successfully differentiate patients with AF from those without it, they require invasive measurement and a ...
... of abnormal atriograms under right atrium mapping,(23) fragmentation of atrial activity elicited by premature stimulation and the vulnerability index.(9,10,24) Although these parameters seem to successfully differentiate patients with AF from those without it, they require invasive measurement and a ...
Long-term Outcomes in Individuals With Prolonged PR
... Main Outcome Measures Incident atrial fibrillation (AF), pacemaker implantation, and all-cause mortality. Results During follow-up, 481 participants developed AF, 124 required pacemaker implantation, and 1739 died. At the baseline examination, 124 individuals had PR intervals longer than 200 millise ...
... Main Outcome Measures Incident atrial fibrillation (AF), pacemaker implantation, and all-cause mortality. Results During follow-up, 481 participants developed AF, 124 required pacemaker implantation, and 1739 died. At the baseline examination, 124 individuals had PR intervals longer than 200 millise ...
clinical usefulness of b-type natriuretic peptide - Heart
... BNP as a screening test for men and women older than 60 years with previous hypertension and known cardiovascular disease, the potential clinical value is limited, as illustrated by an AUC of 0.65 for men and 0.86 for women. Sub-analysis from the North Glasgow cohort identified a group of high risk ...
... BNP as a screening test for men and women older than 60 years with previous hypertension and known cardiovascular disease, the potential clinical value is limited, as illustrated by an AUC of 0.65 for men and 0.86 for women. Sub-analysis from the North Glasgow cohort identified a group of high risk ...
1. NAME OF THE MEDICINAL PRODUCT Cinfaval 80 mg film-coated tablets
... In patients with heart failure, the triple combination of an ACE inhibitor, a beta-blocker and valsartan has shown no clinical benefit (see section 5.1). This combination apparently increases the risk of adverse events and is therefore not recommended. CinfavalCaution should be observed when initiat ...
... In patients with heart failure, the triple combination of an ACE inhibitor, a beta-blocker and valsartan has shown no clinical benefit (see section 5.1). This combination apparently increases the risk of adverse events and is therefore not recommended. CinfavalCaution should be observed when initiat ...
Relationship of the Pulmonary Artery End
... a which could be identified only at the basal heart rate was identical to the LVEDP. In the five patients studied during atrial fibrillation, the LVEDP was found to be equal to the PAEDP in one case and lower than the PAEDP in four, in three of which PVR was increased. The relationship between these ...
... a which could be identified only at the basal heart rate was identical to the LVEDP. In the five patients studied during atrial fibrillation, the LVEDP was found to be equal to the PAEDP in one case and lower than the PAEDP in four, in three of which PVR was increased. The relationship between these ...
SIGN publication no. 35 - Diagnosis and Treatment of Heart Failure
... The following patients should receive treatment with digoxin: § All patients with heart failure and atrial fibrillation who need control of the ventricular rate. § Patients with moderately severe or severely symptomatic (NYHA Class III or IV) heart failure who remain symptomatic despite diuretic and ...
... The following patients should receive treatment with digoxin: § All patients with heart failure and atrial fibrillation who need control of the ventricular rate. § Patients with moderately severe or severely symptomatic (NYHA Class III or IV) heart failure who remain symptomatic despite diuretic and ...
Myocardial Expression of Fas and Recovery of Left
... significant febrile illness within the past year (mean duration between febrile illness and study entry, 5.9 ⫾ 3.6 months). All had a normal white blood cell count at time of entry (mean, 6.9 ⫾ 1.5; range, 4.9 to 10.0 ⫻ 103/mm3). Endomyocardial biopsies were interpreted as negative for myocarditis i ...
... significant febrile illness within the past year (mean duration between febrile illness and study entry, 5.9 ⫾ 3.6 months). All had a normal white blood cell count at time of entry (mean, 6.9 ⫾ 1.5; range, 4.9 to 10.0 ⫻ 103/mm3). Endomyocardial biopsies were interpreted as negative for myocarditis i ...
Conducting tissue of the heart in kwashiorkor - Heart
... the papillary muscles and subendocardially. In case in the present series myocytolysis is involving the left bundle-branch as it lies under tSke endocardium, but no areas of necrosis are seen in the myocardium. r This study has shown atrophic changes in the conducting tissue with kwashiorkor, the fu ...
... the papillary muscles and subendocardially. In case in the present series myocytolysis is involving the left bundle-branch as it lies under tSke endocardium, but no areas of necrosis are seen in the myocardium. r This study has shown atrophic changes in the conducting tissue with kwashiorkor, the fu ...
How should I treat a perimembranous
... PRESENTATION OF THE CASE A 73-year-old man was admitted to our Institute for repeated episodes of congestive heart failure. His past medical history included arterial hypertension, dyslipidaemia, severe chronic obstructive pulmonary disease, prior episodes of lower intestinal bleeding, and recurrent ...
... PRESENTATION OF THE CASE A 73-year-old man was admitted to our Institute for repeated episodes of congestive heart failure. His past medical history included arterial hypertension, dyslipidaemia, severe chronic obstructive pulmonary disease, prior episodes of lower intestinal bleeding, and recurrent ...
results from the PICTURE registry
... Patients were eligible if they had recurrent unexplained syncope or pre-syncope, estimated after the event and not separated in the analysis. The term ‘unexplained’ was not defined in the protocol but the application of the term to a patient and the subsequent decision to implant an ILR and the prog ...
... Patients were eligible if they had recurrent unexplained syncope or pre-syncope, estimated after the event and not separated in the analysis. The term ‘unexplained’ was not defined in the protocol but the application of the term to a patient and the subsequent decision to implant an ILR and the prog ...
Patient Selection for subcutaneous ICD
... a subcutaneous implantable cardioverter defibrillator (ICD) electrode1 was received from Boston Scientific by the Department of Health and Ageing in September 2013. Conventional (transvenous) ICD therapy consists of a generator, which is usually implanted in a pocket in the pectoral region below the ...
... a subcutaneous implantable cardioverter defibrillator (ICD) electrode1 was received from Boston Scientific by the Department of Health and Ageing in September 2013. Conventional (transvenous) ICD therapy consists of a generator, which is usually implanted in a pocket in the pectoral region below the ...
Conducting tissue of the heart in kwashiorkor
... the papillary muscles and subendocardially. In case in the present series myocytolysis is involving the left bundle-branch as it lies under tSke endocardium, but no areas of necrosis are seen in the myocardium. r This study has shown atrophic changes in the conducting tissue with kwashiorkor, the fu ...
... the papillary muscles and subendocardially. In case in the present series myocytolysis is involving the left bundle-branch as it lies under tSke endocardium, but no areas of necrosis are seen in the myocardium. r This study has shown atrophic changes in the conducting tissue with kwashiorkor, the fu ...
EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias
... will not go on to develop cardiomyopathy but currently available data do not allow for accurate risk prediction. A recent longitudinal study followed 239 patients with frequent PVCs (.1000 per day) and no SHD [echo and magnetic resonance imaging (MRI)] for 5.6 years with no adverse cardiac events an ...
... will not go on to develop cardiomyopathy but currently available data do not allow for accurate risk prediction. A recent longitudinal study followed 239 patients with frequent PVCs (.1000 per day) and no SHD [echo and magnetic resonance imaging (MRI)] for 5.6 years with no adverse cardiac events an ...
Electrical cardioversion for atrial fibrillation and flutter
... were entered into RevMan. Main results: We identified two completed studies AFFIRM (n=4060) and PIAF (n=252). We found no difference in mortality between rhythm control and rate control relative risk 1.14 (95% confidence interval 1.00 to 1.31). Both studies show significantly higher rates of hospita ...
... were entered into RevMan. Main results: We identified two completed studies AFFIRM (n=4060) and PIAF (n=252). We found no difference in mortality between rhythm control and rate control relative risk 1.14 (95% confidence interval 1.00 to 1.31). Both studies show significantly higher rates of hospita ...
Obstructive Sleep Apnea and its Relationship to Cardiac Arrhythmias
... OSA and Cardiac Arrhythmias. Obstructive sleep apnea (OSA) affects approximately 4% of middleaged men and 2% of middle-aged women. Cardiac arrhythmias are common problems in patients with OSA, even though the true prevalence and clinical relevance of cardiac arrhythmias remains to be determined. The ...
... OSA and Cardiac Arrhythmias. Obstructive sleep apnea (OSA) affects approximately 4% of middleaged men and 2% of middle-aged women. Cardiac arrhythmias are common problems in patients with OSA, even though the true prevalence and clinical relevance of cardiac arrhythmias remains to be determined. The ...
Non-invasive assessment of cardiac physiology by tissue Doppler
... York Heart Association functional class I; 11 (50%) in class II, and four (20%) in class III. During the examination 19 patients (85%) were in sinus rhythm and three (15%) in atrial fibrillation. ...
... York Heart Association functional class I; 11 (50%) in class II, and four (20%) in class III. During the examination 19 patients (85%) were in sinus rhythm and three (15%) in atrial fibrillation. ...
Anisotropic Reinforcement of Acute Anteroapical Infarcts Improves
... to develop a complementary therapeutic approach that could improve LV pump function early after a large MI. Normal myocardium deforms in a complex 3-dimensional pattern with each heartbeat,22–24 and healing myocardial infarcts can be highly anisotropic (having different mechan ical properties in di ...
... to develop a complementary therapeutic approach that could improve LV pump function early after a large MI. Normal myocardium deforms in a complex 3-dimensional pattern with each heartbeat,22–24 and healing myocardial infarcts can be highly anisotropic (having different mechan ical properties in di ...
ACC/AHA/ESC 2006 Guidelines for Management
... evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered as well as freq ...
... evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered as well as freq ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.